Vaccine Adjuvants Market By Type (Immunostimulants, Vehicles and Mucosal Adjuvants), By Disease (Infectious Diseases, Others), By Application (Research, Commercial): Global Opportunity Analysis and Industry Forecast, 2024-2035
The vaccine adjuvants market was valued at $820.2 million in 2023 and is estimated to reach $1,304.83 million by 2035, exhibiting a CAGR of 3.9% from 2024 to 2035.
Vaccine adjuvants are substances added to vaccines to enhance the body’s immune response to the target antigen, allowing for a stronger, faster, or more prolonged immunity. Functionally, adjuvants work by stimulating immune cells or activating specific immune pathways, by mimicking infection signals that prompt the immune system to initiate a protective response. This response can improve the efficacy of vaccines, reducing the amount of antigen needed or the number of doses required. Vehicular adjuvants enhance stability, transport the antigen, and facilitate the immune system’s recognition and response.
Adjuvants offer advantages such as boosting immunity in older or immunocompromised individuals and enabling broad protection against multiple pathogens. Types of adjuvants include aluminum salts (alum), which are widely used for their safety and efficacy; oil-in-water emulsions like MF59 and AS03, which enhance antigen uptake; and novel types such as liposomes, saponins, and nanoparticle-based adjuvants that offer targeted delivery and controlled release. The adjuvant types are selected based on their ability to enhance immune responses specific to the disease being targeted, thus playing a crucial role in developing effective and efficient vaccines.
The vaccine adjuvants market is driven by rise in demand for more effective vaccines, especially in emerging infectious diseases and chronic conditions. Rise in incidence of infectious diseases, including flu, hepatitis, COVID-19, and various bacterial infections, emphasize the need for innovative vaccine solutions that rovide broad protection,thereby driving the demand for vaccines. For instance, according to an article published by World Health Organization (WHO) in 2023, 116 million people were living with hepatitis B and 10 million with hepatitis C in the Western Pacific Region. This incidence highlights the ongoing need for effective vaccines and adjuvants to support immune responses, particularly in high-risk populations, thereby driving the vaccine adjuvants market growth.
Vaccine adjuvants enhance the immune response to antigens, making vaccines more effective and potentially reducing the number of doses required, which is particularly beneficial in regions with limited healthcare access. In addition, the government funding and initiatives supporting vaccine development also play a significant role in the growth of the vaccine adjuvants market. Agencies such as the World Health Organization (WHO) and governments globally are investing in vaccine research and production to improve global immunization rates. For instance, in August 2023, the U.S. Department of Health and Human Services announced over $1.4 billion in funding through Project NextGen. This includes $1 billion for vaccine clinical trials, $326 million for new monoclonal antibody treatments, and $100 million to explore novel vaccine technologies, aimed at advancing COVID-19 vaccine development and therapeutics.
In addition, rise in collaborations between pharmaceutical companies and research institutions is leading to the development of new adjuvants with enhanced efficacy and safety. For instance, in October 2023, SPI Pharma, Inc., (SPI) and Q-Vant Biosciences, Inc. partnered to leverage Q-Vant's leadership in unique, sustainable saponin extraction technology with SPI's global pharmaceutical reach and expertise in servicing the industry. The investment commitment to expand commercial-scale GMP manufacturing of high-purity saponins, along with the exclusive commercial agreement, will enable global pharma customers to access a sustainable, scalable, and fully integrated supply of saponin adjuvants. These partnerships are accelerating research and development, thus propelling the growth of the vaccine adjuvants market.
However, high costs associated with research, development, and production are expected to restrain the market growth. Adjuvant development requires significant investment in specialized technologies and stringent testing to ensure safety and efficacy, which increases manufacturing costs. For many companies, these high initial costs pose a barrier to entry, limiting the number of players in the market and reducing the competitive landscape. In addition, stringent regulatory requirements for vaccine adjuvants, particularly in regions with rigorous approval standards, further restrict the market growth.
However, rise in vaccination programs in emerging countries, along with a focus on personalized and therapeutic vaccines, further enhance growth opportunities for the market, as more pharmaceutical and biotech companies invest in new adjuvant technologies to meet diverse and growing healthcare needs globally. In addition, rise in advancements in vaccine development and high growth potential in emerging countries provide an opportunity for the market growth.
The vaccine adjuvants market is segmented into type, disease, application, and region. By type, the market is bifurcated into immunostimulants and vehicles & mucosal adjuvants. The immunostimulants segment is further classified into toll-like receptor (TLR) and others. By disease, the market is segregated into infectious diseases and others. The infectious diseases segment is further classified into hepatitis and others. By application, the market is bifurcated into research and commercial. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India,Australia, South Korea, and rest of Asia-Pacific), and Latin America (Brazil, Colombia, Argentina, and Rest of LA), and Middle East Africa (GCC, South Africa, North Africa, and Rest of MEA).
Major key players that operate in the global vaccine adjuvants market are Dynavax Technologies Corporation , Novovax, Agenus Inc., Adjuvatis, Air Liquide Group, Aurorium, InvivoGen, Associated British Foods, GlaxoSmithKline plc., and Croda International Plc. Key players operating in the market have adopted agreement, acquisition, partnership, clinical trials, and product approval as their key strategies to expand their product portfolio. For instance, in May 2024, Novavax, Inc. entered into a co-exclusive licensing agreement with Sanofi. The terms of the agreement include a co-exclusive license to co-commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccine adjuvants market analysis from 2023 to 2035 to identify the prevailing vaccine adjuvants market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the vaccine adjuvants market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global vaccine adjuvants market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
Immunostimulants
Type
Toll like receptor
Others
Vehicles and Mucosal Adjuvants
By Disease
Infectious Diseases
Type
Hepatitis
Others
Others
By Application
Research
Commercial
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
Latin America
Brazil
Colombia
Argentina
Rest of Latin America
Middle East and Africa
Gcc
South Africa
North Africa
Rest of Middle East And Africa
Key Market Players
Agenus Inc.
Novovax Inc.
Aurorium
Air Liquide Group
Adjuvatis
InvivoGen
Associated British Foods
GlaxoSmithKline plc.
Croda International Plc
Dynavax Technologies Corporation
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Moderate intensity of rivalry
- 3.3.2. Moderate bargaining power of buyers
- 3.3.3. Moderate bargaining power of suppliers
- 3.3.4. High threat of new entrants
- 3.3.5. Moderate threat of substitutes
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increase in prevalence of infectious diseases
- 3.4.1.2. Growing funding for vaccines and infectious diseases
- 3.4.1.3. Expansion of vaccination programs
- 3.4.2. Restraints
- 3.4.2.1. High initial and R&D cost
- 3.4.3. Opportunities
- 3.4.3.1. Growth opportunities in emerging markets
- 3.4.3.2. Advancements in vaccine adjuvant research
- CHAPTER 4: VACCINE ADJUVANTS MARKET, BY TYPE
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Immunostimulants
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. Immunostimulants Vaccine Adjuvants Market by Type
- 4.3. Vehicles and Mucosal Adjuvants
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- CHAPTER 5: VACCINE ADJUVANTS MARKET, BY DISEASE
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Infectious Diseases
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.2.4. Infectious Diseases Vaccine Adjuvants Market by Type
- 5.3. Others
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- CHAPTER 6: VACCINE ADJUVANTS MARKET, BY APPLICATION
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Research
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Commercial
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- CHAPTER 7: VACCINE ADJUVANTS MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Disease
- 7.2.4. Market size and forecast, by Application
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Market size and forecast, by Type
- 7.2.5.1.2. Market size and forecast, by Disease
- 7.2.5.1.3. Market size and forecast, by Application
- 7.2.5.2. Canada
- 7.2.5.2.1. Market size and forecast, by Type
- 7.2.5.2.2. Market size and forecast, by Disease
- 7.2.5.2.3. Market size and forecast, by Application
- 7.2.5.3. Mexico
- 7.2.5.3.1. Market size and forecast, by Type
- 7.2.5.3.2. Market size and forecast, by Disease
- 7.2.5.3.3. Market size and forecast, by Application
- 7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Disease
- 7.3.4. Market size and forecast, by Application
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Market size and forecast, by Type
- 7.3.5.1.2. Market size and forecast, by Disease
- 7.3.5.1.3. Market size and forecast, by Application
- 7.3.5.2. France
- 7.3.5.2.1. Market size and forecast, by Type
- 7.3.5.2.2. Market size and forecast, by Disease
- 7.3.5.2.3. Market size and forecast, by Application
- 7.3.5.3. UK
- 7.3.5.3.1. Market size and forecast, by Type
- 7.3.5.3.2. Market size and forecast, by Disease
- 7.3.5.3.3. Market size and forecast, by Application
- 7.3.5.4. Italy
- 7.3.5.4.1. Market size and forecast, by Type
- 7.3.5.4.2. Market size and forecast, by Disease
- 7.3.5.4.3. Market size and forecast, by Application
- 7.3.5.5. Spain
- 7.3.5.5.1. Market size and forecast, by Type
- 7.3.5.5.2. Market size and forecast, by Disease
- 7.3.5.5.3. Market size and forecast, by Application
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Market size and forecast, by Type
- 7.3.5.6.2. Market size and forecast, by Disease
- 7.3.5.6.3. Market size and forecast, by Application
- 7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Disease
- 7.4.4. Market size and forecast, by Application
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Market size and forecast, by Type
- 7.4.5.1.2. Market size and forecast, by Disease
- 7.4.5.1.3. Market size and forecast, by Application
- 7.4.5.2. China
- 7.4.5.2.1. Market size and forecast, by Type
- 7.4.5.2.2. Market size and forecast, by Disease
- 7.4.5.2.3. Market size and forecast, by Application
- 7.4.5.3. India
- 7.4.5.3.1. Market size and forecast, by Type
- 7.4.5.3.2. Market size and forecast, by Disease
- 7.4.5.3.3. Market size and forecast, by Application
- 7.4.5.4. Australia
- 7.4.5.4.1. Market size and forecast, by Type
- 7.4.5.4.2. Market size and forecast, by Disease
- 7.4.5.4.3. Market size and forecast, by Application
- 7.4.5.5. South Korea
- 7.4.5.5.1. Market size and forecast, by Type
- 7.4.5.5.2. Market size and forecast, by Disease
- 7.4.5.5.3. Market size and forecast, by Application
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Market size and forecast, by Type
- 7.4.5.6.2. Market size and forecast, by Disease
- 7.4.5.6.3. Market size and forecast, by Application
- 7.5. Latin America
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Disease
- 7.5.4. Market size and forecast, by Application
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Market size and forecast, by Type
- 7.5.5.1.2. Market size and forecast, by Disease
- 7.5.5.1.3. Market size and forecast, by Application
- 7.5.5.2. Colombia
- 7.5.5.2.1. Market size and forecast, by Type
- 7.5.5.2.2. Market size and forecast, by Disease
- 7.5.5.2.3. Market size and forecast, by Application
- 7.5.5.3. Argentina
- 7.5.5.3.1. Market size and forecast, by Type
- 7.5.5.3.2. Market size and forecast, by Disease
- 7.5.5.3.3. Market size and forecast, by Application
- 7.5.5.4. Rest of Latin America
- 7.5.5.4.1. Market size and forecast, by Type
- 7.5.5.4.2. Market size and forecast, by Disease
- 7.5.5.4.3. Market size and forecast, by Application
- 7.6. Middle East and Africa
- 7.6.1. Key market trends, growth factors and opportunities
- 7.6.2. Market size and forecast, by Type
- 7.6.3. Market size and forecast, by Disease
- 7.6.4. Market size and forecast, by Application
- 7.6.5. Market size and forecast, by country
- 7.6.5.1. Gcc
- 7.6.5.1.1. Market size and forecast, by Type
- 7.6.5.1.2. Market size and forecast, by Disease
- 7.6.5.1.3. Market size and forecast, by Application
- 7.6.5.2. South Africa
- 7.6.5.2.1. Market size and forecast, by Type
- 7.6.5.2.2. Market size and forecast, by Disease
- 7.6.5.2.3. Market size and forecast, by Application
- 7.6.5.3. North Africa
- 7.6.5.3.1. Market size and forecast, by Type
- 7.6.5.3.2. Market size and forecast, by Disease
- 7.6.5.3.3. Market size and forecast, by Application
- 7.6.5.4. Rest of Middle East And Africa
- 7.6.5.4.1. Market size and forecast, by Type
- 7.6.5.4.2. Market size and forecast, by Disease
- 7.6.5.4.3. Market size and forecast, by Application
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product mapping of top 10 player
- 8.4. Competitive dashboard
- 8.5. Competitive heatmap
- 8.6. Top player positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Dynavax Technologies Corporation
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Novovax Inc.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Agenus Inc.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. Adjuvatis
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.5. Aurorium
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Key strategic moves and developments
- 9.6. InvivoGen
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.7. Croda International Plc
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. Air Liquide Group
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.9. Associated British Foods
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
- 9.10. GlaxoSmithKline plc.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. GLOBAL VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 02. VACCINE ADJUVANTS MARKET FOR IMMUNOSTIMULANTS, BY REGION, 2023-2035 ($MILLION)
- TABLE 03. GLOBAL IMMUNOSTIMULANTS VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 04. VACCINE ADJUVANTS MARKET FOR VEHICLES AND MUCOSAL ADJUVANTS, BY REGION, 2023-2035 ($MILLION)
- TABLE 05. GLOBAL VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 06. VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2035 ($MILLION)
- TABLE 07. GLOBAL INFECTIOUS DISEASES VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 08. VACCINE ADJUVANTS MARKET FOR OTHERS, BY REGION, 2023-2035 ($MILLION)
- TABLE 09. GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 10. VACCINE ADJUVANTS MARKET FOR RESEARCH, BY REGION, 2023-2035 ($MILLION)
- TABLE 11. VACCINE ADJUVANTS MARKET FOR COMMERCIAL, BY REGION, 2023-2035 ($MILLION)
- TABLE 12. VACCINE ADJUVANTS MARKET, BY REGION, 2023-2035 ($MILLION)
- TABLE 13. NORTH AMERICA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 14. NORTH AMERICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 15. NORTH AMERICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 16. NORTH AMERICA VACCINE ADJUVANTS MARKET, BY COUNTRY, 2023-2035 ($MILLION)
- TABLE 17. U.S. VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 18. U.S. VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 19. U.S. VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 20. CANADA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 21. CANADA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 22. CANADA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 23. MEXICO VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 24. MEXICO VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 25. MEXICO VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 26. EUROPE VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 27. EUROPE VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 28. EUROPE VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 29. EUROPE VACCINE ADJUVANTS MARKET, BY COUNTRY, 2023-2035 ($MILLION)
- TABLE 30. GERMANY VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 31. GERMANY VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 32. GERMANY VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 33. FRANCE VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 34. FRANCE VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 35. FRANCE VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 36. UK VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 37. UK VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 38. UK VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 39. ITALY VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 40. ITALY VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 41. ITALY VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 42. SPAIN VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 43. SPAIN VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 44. SPAIN VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 45. REST OF EUROPE VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 46. REST OF EUROPE VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 47. REST OF EUROPE VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 48. ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 49. ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 50. ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 51. ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2023-2035 ($MILLION)
- TABLE 52. JAPAN VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 53. JAPAN VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 54. JAPAN VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 55. CHINA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 56. CHINA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 57. CHINA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 58. INDIA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 59. INDIA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 60. INDIA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 61. AUSTRALIA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 62. AUSTRALIA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 63. AUSTRALIA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 64. SOUTH KOREA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 65. SOUTH KOREA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 66. SOUTH KOREA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 67. REST OF ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 68. REST OF ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 69. REST OF ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 70. LATIN AMERICA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 71. LATIN AMERICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 72. LATIN AMERICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 73. LATIN AMERICA VACCINE ADJUVANTS MARKET, BY COUNTRY, 2023-2035 ($MILLION)
- TABLE 74. BRAZIL VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 75. BRAZIL VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 76. BRAZIL VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 77. COLOMBIA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 78. COLOMBIA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 79. COLOMBIA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 80. ARGENTINA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 81. ARGENTINA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 82. ARGENTINA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 83. REST OF LATIN AMERICA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 84. REST OF LATIN AMERICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 85. REST OF LATIN AMERICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 86. MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 87. MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 88. MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 89. MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY COUNTRY, 2023-2035 ($MILLION)
- TABLE 90. GCC VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 91. GCC VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 92. GCC VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 93. SOUTH AFRICA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 94. SOUTH AFRICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 95. SOUTH AFRICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 96. NORTH AFRICA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 97. NORTH AFRICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 98. NORTH AFRICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 99. REST OF MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY TYPE, 2023-2035 ($MILLION)
- TABLE 100. REST OF MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2023-2035 ($MILLION)
- TABLE 101. REST OF MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
- TABLE 102. DYNAVAX TECHNOLOGIES CORPORATION: KEY EXECUTIVES
- TABLE 103. DYNAVAX TECHNOLOGIES CORPORATION: COMPANY SNAPSHOT
- TABLE 104. DYNAVAX TECHNOLOGIES CORPORATION: PRODUCT SEGMENTS
- TABLE 105. DYNAVAX TECHNOLOGIES CORPORATION: PRODUCT PORTFOLIO
- TABLE 106. DYNAVAX TECHNOLOGIES CORPORATION: KEY STRATERGIES
- TABLE 107. NOVOVAX INC.: KEY EXECUTIVES
- TABLE 108. NOVOVAX INC.: COMPANY SNAPSHOT
- TABLE 109. NOVOVAX INC.: PRODUCT SEGMENTS
- TABLE 110. NOVOVAX INC.: PRODUCT PORTFOLIO
- TABLE 111. NOVOVAX INC.: KEY STRATERGIES
- TABLE 112. AGENUS INC.: KEY EXECUTIVES
- TABLE 113. AGENUS INC.: COMPANY SNAPSHOT
- TABLE 114. AGENUS INC.: PRODUCT SEGMENTS
- TABLE 115. AGENUS INC.: PRODUCT PORTFOLIO
- TABLE 116. AGENUS INC.: KEY STRATERGIES
- TABLE 117. ADJUVATIS: KEY EXECUTIVES
- TABLE 118. ADJUVATIS: COMPANY SNAPSHOT
- TABLE 119. ADJUVATIS: PRODUCT SEGMENTS
- TABLE 120. ADJUVATIS: SERVICE SEGMENTS
- TABLE 121. ADJUVATIS: PRODUCT PORTFOLIO
- TABLE 122. AURORIUM: KEY EXECUTIVES
- TABLE 123. AURORIUM: COMPANY SNAPSHOT
- TABLE 124. AURORIUM: PRODUCT SEGMENTS
- TABLE 125. AURORIUM: PRODUCT PORTFOLIO
- TABLE 126. AURORIUM: KEY STRATERGIES
- TABLE 127. INVIVOGEN: KEY EXECUTIVES
- TABLE 128. INVIVOGEN: COMPANY SNAPSHOT
- TABLE 129. INVIVOGEN: PRODUCT SEGMENTS
- TABLE 130. INVIVOGEN: SERVICE SEGMENTS
- TABLE 131. INVIVOGEN: PRODUCT PORTFOLIO
- TABLE 132. CRODA INTERNATIONAL PLC: KEY EXECUTIVES
- TABLE 133. CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT
- TABLE 134. CRODA INTERNATIONAL PLC: PRODUCT SEGMENTS
- TABLE 135. CRODA INTERNATIONAL PLC: PRODUCT PORTFOLIO
- TABLE 136. CRODA INTERNATIONAL PLC: KEY STRATERGIES
- TABLE 137. AIR LIQUIDE GROUP: KEY EXECUTIVES
- TABLE 138. AIR LIQUIDE GROUP: COMPANY SNAPSHOT
- TABLE 139. AIR LIQUIDE GROUP: PRODUCT SEGMENTS
- TABLE 140. AIR LIQUIDE GROUP: PRODUCT PORTFOLIO
- TABLE 141. ASSOCIATED BRITISH FOODS: KEY EXECUTIVES
- TABLE 142. ASSOCIATED BRITISH FOODS: COMPANY SNAPSHOT
- TABLE 143. ASSOCIATED BRITISH FOODS: PRODUCT SEGMENTS
- TABLE 144. ASSOCIATED BRITISH FOODS: PRODUCT PORTFOLIO
- TABLE 145. ASSOCIATED BRITISH FOODS: KEY STRATERGIES
- TABLE 146. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
- TABLE 147. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
- TABLE 148. GLAXOSMITHKLINE PLC.: PRODUCT SEGMENTS
- TABLE 149. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
- TABLE 150. GLAXOSMITHKLINE PLC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. VACCINE ADJUVANTS MARKET, 2023-2035
- FIGURE 02. SEGMENTATION OF VACCINE ADJUVANTS MARKET,2023-2035
- FIGURE 03. TOP IMPACTING FACTORS IN VACCINE ADJUVANTS MARKET (2023 TO 2035)
- FIGURE 04. TOP INVESTMENT POCKETS IN VACCINE ADJUVANTS MARKET (2024-2035)
- FIGURE 05. MODERATE INTENSITY OF RIVALRY
- FIGURE 06. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 07. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 08. HIGH THREAT OF NEW ENTRANTS
- FIGURE 09. MODERATE THREAT OF SUBSTITUTES
- FIGURE 10. GLOBAL VACCINE ADJUVANTS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11. VACCINE ADJUVANTS MARKET, BY TYPE, 2023 AND 2035(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR IMMUNOSTIMULANTS, BY COUNTRY 2023 AND 2035(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR VEHICLES AND MUCOSAL ADJUVANTS, BY COUNTRY 2023 AND 2035(%)
- FIGURE 14. VACCINE ADJUVANTS MARKET, BY DISEASE, 2023 AND 2035(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2023 AND 2035(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2035(%)
- FIGURE 17. VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023 AND 2035(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR RESEARCH, BY COUNTRY 2023 AND 2035(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR COMMERCIAL, BY COUNTRY 2023 AND 2035(%)
- FIGURE 20. VACCINE ADJUVANTS MARKET BY REGION, 2023 AND 2035(%)
- FIGURE 21. U.S. VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 22. CANADA VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 23. MEXICO VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 24. GERMANY VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 25. FRANCE VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 26. UK VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 27. ITALY VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 28. SPAIN VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 29. REST OF EUROPE VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 30. JAPAN VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 31. CHINA VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 32. INDIA VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 33. AUSTRALIA VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 34. SOUTH KOREA VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 35. REST OF ASIA-PACIFIC VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 36. BRAZIL VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 37. COLOMBIA VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 38. ARGENTINA VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 39. REST OF LATIN AMERICA VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 40. GCC VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 41. SOUTH AFRICA VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 42. NORTH AFRICA VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 43. REST OF MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, 2023-2035 ($MILLION)
- FIGURE 44. TOP WINNING STRATEGIES, BY YEAR (2021-2024)
- FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2024)
- FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY (2021-2024)
- FIGURE 47. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 48. COMPETITIVE DASHBOARD
- FIGURE 49. COMPETITIVE HEATMAP: VACCINE ADJUVANTS MARKET
- FIGURE 50. TOP PLAYER POSITIONING, 2023
- FIGURE 51. DYNAVAX TECHNOLOGIES CORPORATION: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 52. DYNAVAX TECHNOLOGIES CORPORATION: REVENUE SHARE BY REGION, 2023 (%)
- FIGURE 53. NOVOVAX INC.: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 54. AGENUS INC.: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 55. AGENUS INC.: REVENUE SHARE BY REGION, 2023 (%)
- FIGURE 56. CRODA INTERNATIONAL PLC: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 57. CRODA INTERNATIONAL PLC: REVENUE SHARE BY SEGMENT, 2023 (%)
- FIGURE 58. CRODA INTERNATIONAL PLC: REVENUE SHARE BY REGION, 2023 (%)
- FIGURE 59. AIR LIQUIDE GROUP: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 60. ASSOCIATED BRITISH FOODS: NET REVENUE, 2022-2024 ($MILLION)
- FIGURE 61. ASSOCIATED BRITISH FOODS: REVENUE SHARE BY SEGMENT, 2024 (%)
- FIGURE 62. ASSOCIATED BRITISH FOODS: REVENUE SHARE BY REGION, 2024 (%)
- FIGURE 63. GSK PLC.: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 64. GSK PLC.: REVENUE SHARE BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook